TFF Pharmaceuticals Revenue and Competitors

Austin, TX USA

Location

#5366

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • TFF Pharmaceuticals's estimated annual revenue is currently $3.2M per year.(i)
  • TFF Pharmaceuticals's total funding is $22M.

Employee Data

    TFF Pharmaceuticals's People

    NameTitleEmail/Phone
    1
    CFOReveal Email/Phone
    2
    Chief Operating Officer and VP, Business DevelopmentReveal Email/Phone
    3
    CEOReveal Email/Phone
    4
    VP Government and Strategic InitiativesReveal Email/Phone
    5
    Director, Global Strategic Marketing and AnalyticsReveal Email/Phone
    6
    Chief Medical OfficerReveal Email/Phone
    7
    Manager, Process EngineeringReveal Email/Phone
    Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
    #1
    $26.7M13320%N/AN/A
    #2
    $13.5M676%N/AN/A
    #3
    $16.1M7717%N/AN/A
    #4
    $62.5M0N/AN/AN/A
    #5
    $10.1M506%N/AN/A
    #6
    $119.4M75738%N/AN/A
    #7
    $22.9M1148%N/AN/A
    #8
    $92.9M4628%N/AN/A
    #9
    $11.3M5111%N/AN/A
    #10
    $7M3314%N/AN/A
    Add Company

    What Is TFF Pharmaceuticals?

    TFF Pharmaceuticals, Inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology. Our patented Thin Film Freezing (TFF) platform makes it possible to turn more molecules into inhalable therapies. This novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally.

    keywords:N/A

    $22M

    Total Funding

    N/A

    Number of Employees

    $3.2M

    Revenue (est)

    N/A

    Employee Growth %

    N/A

    Valuation

    N/A

    Accelerator

    TFF Pharmaceuticals News

    2022-04-17 - TFF Pharmaceuticals Announces Safety and Pharmacokinetic ...

    TFF Pharmaceuticals believes the 6 mg dose level of Niclosamide Inhalation Powder is estimated to produce a concentration of 100 ?M in the...

    2022-03-22 - TFF Pharmaceuticals, Inc. (TFFP) Q4 2021 Earnings Call ...

    TFF Pharmaceuticals, Inc. ( TFFP -2.85% ) Q4 2021 Earnings Call Mar 24, 2022, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and...

    2022-03-22 - Looking Into TFF Pharmaceuticals's Return On Capital Employed - Benzinga

    Benzinga Pro data, TFF Pharmaceuticals. TFFP-6.33%+ Free Alerts. reported Q4 sales of $12.00 thousand. Earnings fell to a loss of $10.05...

    2021-11-08 - TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

    Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceu ...

    2021-09-23 - TFF Pharmaceuticals : Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

    AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced topline re ...